Neue Substanzen in der medikamentösen Therapie des metastasierten Pankreaskarzinoms – Was ist Standard nach Leitlinie für wen, welche Therapiesequenz, was ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-05-24

AUTHORS

Ursula Pluschnig

ABSTRACT

Recently, an improvement in the therapy of the metastatic pancreatic cancer (PC) has been achieved. In first-line therapy, in addition to standard chemotherapy with gemcitabine, new therapy combinations such as nab-paclitaxel/gemcitabine and FOLFIRINOX have been established. The indication for second-line therapy after progression is based on the ECOG performance status, clinical parameters (bilirubin), and the type of pretreatment in the first line. Since 2016, a new substance has been established with nanoliposomal irinotecan (nal-IRI) plus 5‑FU/LV. New therapeutic approaches in patients with germ-line mutations (often BRCA1, BRCA2, PALB2 and the ATM genes) and immunological therapeutic approaches with checkpoint inhibitors are being investigated in recent studies. Data on stromal hyaluronic acid content raise hopes for a clinically relevant biomarker for pancreatic cancer therapy. Within the framework of personalized therapy using whole-genome sequencing (WGS) and RNA sequencing (RNA-Seq), molecular markers can be measured. Palliative therapy focuses on the following: symptom control; nutrition; enzyme, diabetes and vitamin therapy; pain management; psycho-oncological support. More... »

PAGES

49-55

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s41971-018-0027-9

DOI

http://dx.doi.org/10.1007/s41971-018-0027-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104214299


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Abteilung f\u00fcr Innere Medizin und Onkologie, Klinikum Klagenfurt am W\u00f6rthersee, Feschnigstra\u00dfe\u00a011, 9020, Klagenfurt, \u00d6sterreich", 
          "id": "http://www.grid.ac/institutes/grid.415431.6", 
          "name": [
            "Abteilung f\u00fcr Innere Medizin und Onkologie, Klinikum Klagenfurt am W\u00f6rthersee, Feschnigstra\u00dfe\u00a011, 9020, Klagenfurt, \u00d6sterreich"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pluschnig", 
        "givenName": "Ursula", 
        "id": "sg:person.0772625441.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772625441.46"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nature14169", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027837321", 
          "https://doi.org/10.1038/nature14169"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-05-24", 
    "datePublishedReg": "2018-05-24", 
    "description": "Recently, an improvement in the therapy of the metastatic pancreatic cancer (PC) has been achieved. In first-line therapy, in addition to standard chemotherapy with gemcitabine, new therapy combinations such as nab-paclitaxel/gemcitabine and FOLFIRINOX have been established. The indication for second-line therapy after progression is based on the ECOG performance status, clinical parameters (bilirubin), and the type of pretreatment in the first line. Since 2016, a\u00a0new substance has been established with nanoliposomal irinotecan (nal-IRI) plus 5\u2011FU/LV. New therapeutic approaches in patients with germ-line mutations (often BRCA1, BRCA2, PALB2 and the ATM genes) and immunological therapeutic approaches with checkpoint inhibitors are being investigated in recent studies. Data on stromal hyaluronic acid content raise hopes for a\u00a0clinically relevant biomarker for pancreatic cancer therapy. Within the framework of personalized therapy using whole-genome sequencing (WGS) and RNA sequencing (RNA-Seq), molecular markers can be measured. Palliative therapy focuses on the following: symptom control; nutrition; enzyme, diabetes and vitamin therapy; pain management; psycho-oncological support.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s41971-018-0027-9", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1035274", 
        "issn": [
          "1728-6263", 
          "1728-6271"
        ], 
        "name": "Journal f\u00fcr Gastroenterologische und Hepatologische Erkrankungen", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "16"
      }
    ], 
    "keywords": [
      "pancreatic cancer", 
      "therapeutic approaches", 
      "second-line therapy", 
      "psycho-oncological support", 
      "first-line therapy", 
      "nab-paclitaxel/gemcitabine", 
      "immunological therapeutic approaches", 
      "ECOG performance status", 
      "metastatic pancreatic cancer", 
      "pancreatic cancer therapy", 
      "new therapeutic approaches", 
      "germ-line mutations", 
      "nanoliposomal irinotecan", 
      "performance status", 
      "symptom control", 
      "standard chemotherapy", 
      "checkpoint inhibitors", 
      "palliative therapy", 
      "pain management", 
      "hyaluronic acid content", 
      "vitamin therapy", 
      "clinical parameters", 
      "therapy combinations", 
      "therapy", 
      "relevant biomarkers", 
      "first line", 
      "personalized therapy", 
      "whole-genome sequencing", 
      "cancer therapy", 
      "gemcitabine", 
      "Recent studies", 
      "FOLFIRINOX", 
      "chemotherapy", 
      "irinotecan", 
      "patients", 
      "diabetes", 
      "RNA sequencing", 
      "cancer", 
      "new substances", 
      "LV", 
      "progression", 
      "biomarkers", 
      "molecular markers", 
      "markers", 
      "inhibitors", 
      "nutrition", 
      "pretreatment", 
      "indications", 
      "status", 
      "sequencing", 
      "mutations", 
      "management", 
      "control", 
      "study", 
      "substances", 
      "acid content", 
      "improvement", 
      "enzyme", 
      "hope", 
      "combination", 
      "type of pretreatment", 
      "addition", 
      "data", 
      "support", 
      "lines", 
      "types", 
      "standards", 
      "approach", 
      "de", 
      "content", 
      "parameters", 
      "DERs", 
      "Wen", 
      "framework", 
      "Zukunft", 
      "new therapy combinations", 
      "stromal hyaluronic acid content", 
      "Neue Substanzen", 
      "Substanzen", 
      "Therapie des", 
      "Pankreaskarzinoms \u2013 Was ist Standard", 
      "ist Standard", 
      "Leitlinie f\u00fcr wen", 
      "f\u00fcr wen", 
      "welche Therapiesequenz", 
      "Therapiesequenz"
    ], 
    "name": "Neue Substanzen in der medikament\u00f6sen Therapie des metastasierten Pankreaskarzinoms \u2013 Was ist Standard nach Leitlinie f\u00fcr wen, welche Therapiesequenz, was bringt die Zukunft?", 
    "pagination": "49-55", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104214299"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s41971-018-0027-9"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s41971-018-0027-9", 
      "https://app.dimensions.ai/details/publication/pub.1104214299"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_778.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s41971-018-0027-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0027-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0027-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0027-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s41971-018-0027-9'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      22 PREDICATES      112 URIs      103 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s41971-018-0027-9 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N7d8258a62c2c418abf5bab7d15e0c596
4 schema:citation sg:pub.10.1038/nature14169
5 schema:datePublished 2018-05-24
6 schema:datePublishedReg 2018-05-24
7 schema:description Recently, an improvement in the therapy of the metastatic pancreatic cancer (PC) has been achieved. In first-line therapy, in addition to standard chemotherapy with gemcitabine, new therapy combinations such as nab-paclitaxel/gemcitabine and FOLFIRINOX have been established. The indication for second-line therapy after progression is based on the ECOG performance status, clinical parameters (bilirubin), and the type of pretreatment in the first line. Since 2016, a new substance has been established with nanoliposomal irinotecan (nal-IRI) plus 5‑FU/LV. New therapeutic approaches in patients with germ-line mutations (often BRCA1, BRCA2, PALB2 and the ATM genes) and immunological therapeutic approaches with checkpoint inhibitors are being investigated in recent studies. Data on stromal hyaluronic acid content raise hopes for a clinically relevant biomarker for pancreatic cancer therapy. Within the framework of personalized therapy using whole-genome sequencing (WGS) and RNA sequencing (RNA-Seq), molecular markers can be measured. Palliative therapy focuses on the following: symptom control; nutrition; enzyme, diabetes and vitamin therapy; pain management; psycho-oncological support.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N25ad266fd0dc4bad82065430cf976ebc
12 N4e45f7b1c2664bb5bef0c1434beea7d7
13 sg:journal.1035274
14 schema:keywords DERs
15 ECOG performance status
16 FOLFIRINOX
17 LV
18 Leitlinie für wen
19 Neue Substanzen
20 Pankreaskarzinoms – Was ist Standard
21 RNA sequencing
22 Recent studies
23 Substanzen
24 Therapie des
25 Therapiesequenz
26 Wen
27 Zukunft
28 acid content
29 addition
30 approach
31 biomarkers
32 cancer
33 cancer therapy
34 checkpoint inhibitors
35 chemotherapy
36 clinical parameters
37 combination
38 content
39 control
40 data
41 de
42 diabetes
43 enzyme
44 first line
45 first-line therapy
46 framework
47 für wen
48 gemcitabine
49 germ-line mutations
50 hope
51 hyaluronic acid content
52 immunological therapeutic approaches
53 improvement
54 indications
55 inhibitors
56 irinotecan
57 ist Standard
58 lines
59 management
60 markers
61 metastatic pancreatic cancer
62 molecular markers
63 mutations
64 nab-paclitaxel/gemcitabine
65 nanoliposomal irinotecan
66 new substances
67 new therapeutic approaches
68 new therapy combinations
69 nutrition
70 pain management
71 palliative therapy
72 pancreatic cancer
73 pancreatic cancer therapy
74 parameters
75 patients
76 performance status
77 personalized therapy
78 pretreatment
79 progression
80 psycho-oncological support
81 relevant biomarkers
82 second-line therapy
83 sequencing
84 standard chemotherapy
85 standards
86 status
87 stromal hyaluronic acid content
88 study
89 substances
90 support
91 symptom control
92 therapeutic approaches
93 therapy
94 therapy combinations
95 type of pretreatment
96 types
97 vitamin therapy
98 welche Therapiesequenz
99 whole-genome sequencing
100 schema:name Neue Substanzen in der medikamentösen Therapie des metastasierten Pankreaskarzinoms – Was ist Standard nach Leitlinie für wen, welche Therapiesequenz, was bringt die Zukunft?
101 schema:pagination 49-55
102 schema:productId N9fd0d32c686847168c89445f3f4f44d1
103 Nad9d7cf205a74fec978e2814f02d7f1e
104 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104214299
105 https://doi.org/10.1007/s41971-018-0027-9
106 schema:sdDatePublished 2021-11-01T18:33
107 schema:sdLicense https://scigraph.springernature.com/explorer/license/
108 schema:sdPublisher N2e27165400db4ae394bcd077d2ea8747
109 schema:url https://doi.org/10.1007/s41971-018-0027-9
110 sgo:license sg:explorer/license/
111 sgo:sdDataset articles
112 rdf:type schema:ScholarlyArticle
113 N25ad266fd0dc4bad82065430cf976ebc schema:volumeNumber 16
114 rdf:type schema:PublicationVolume
115 N2e27165400db4ae394bcd077d2ea8747 schema:name Springer Nature - SN SciGraph project
116 rdf:type schema:Organization
117 N4e45f7b1c2664bb5bef0c1434beea7d7 schema:issueNumber 2
118 rdf:type schema:PublicationIssue
119 N7d8258a62c2c418abf5bab7d15e0c596 rdf:first sg:person.0772625441.46
120 rdf:rest rdf:nil
121 N9fd0d32c686847168c89445f3f4f44d1 schema:name doi
122 schema:value 10.1007/s41971-018-0027-9
123 rdf:type schema:PropertyValue
124 Nad9d7cf205a74fec978e2814f02d7f1e schema:name dimensions_id
125 schema:value pub.1104214299
126 rdf:type schema:PropertyValue
127 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
128 schema:name Medical and Health Sciences
129 rdf:type schema:DefinedTerm
130 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
131 schema:name Oncology and Carcinogenesis
132 rdf:type schema:DefinedTerm
133 sg:journal.1035274 schema:issn 1728-6263
134 1728-6271
135 schema:name Journal für Gastroenterologische und Hepatologische Erkrankungen
136 schema:publisher Springer Nature
137 rdf:type schema:Periodical
138 sg:person.0772625441.46 schema:affiliation grid-institutes:grid.415431.6
139 schema:familyName Pluschnig
140 schema:givenName Ursula
141 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0772625441.46
142 rdf:type schema:Person
143 sg:pub.10.1038/nature14169 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027837321
144 https://doi.org/10.1038/nature14169
145 rdf:type schema:CreativeWork
146 grid-institutes:grid.415431.6 schema:alternateName Abteilung für Innere Medizin und Onkologie, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Österreich
147 schema:name Abteilung für Innere Medizin und Onkologie, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Österreich
148 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...